The difference between playing the stock market and the horses is that one of the horses must win.” - Joey Adams ...

Argenica Therapeutics (ASX:AGN), has announced fabulous results from a pilot study assessing the efficacy of lead drug ...

Good afternoon, everyone, and welcome to the Panbela Therapeutics first-quarter 2024 earnings call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the ...

May 7, 2024 Agenus Inc. beats earnings expectations. Reported EPS is $-3.04104, expectations were $-3.1. AGEN isn't one of ...

As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by ...

Cipla's US sales likely to surge in Q4, driven by the contribution from Revlimid, along with a stable market share in ...

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients ...

469. Patrick Soon-Shiong, MD, $5.8 billion, was a practicing physician before inventing the cancer medication Abraxane. He attended the University of British Columbia in Vancouver and the University ...

Analysts' assessment points toward 'Net Sales- Recent LOE Products- Abraxane' reaching $237.80 million. The estimate indicates a year-over-year change of -0.5%. The collective assessment of ...

The ASPIRE trial, which is evaluating the efficacy and safety of Panbela's lead product candidate, ivospemin (SBP-101), in combination with gemcitabine and nab-paclitaxel (Abraxane) in patients ...